p.95 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e366

CLINICAL STATEMENTS AND GUIDELINES S7.1.1.2-2.	 Saxon LA, Wiener I, Natterson PD, et al. Monomorphic versus poly-

morphic ventricular tachycardia after coronary artery bypass grafting. Am J Cardiol. 1995;75:403–5. S7.1.1.2-3.	 Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventricular tachycardia after cardiac surgery. Circulation. 1999;99:903–8. S7.1.1.2-4.	 Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronaryartery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569–75. S7.1.1.2-5.	 Vakil K, Florea V, Koene R, et al. Effect of coronary artery bypass grafting on left ventricular ejection fraction in men eligible for implantable cardioverter-defibrillator. Am J Cardiol. 2016;117:957–60. S7.1.1.2-6.	 Mittal S, Lomnitz DJ, Mirchandani S, et al. Prognostic significance of nonsustained ventricular tachycardia after revascularization. J Cardiovasc Electrophysiol. 2002;13:342–6. S7.1.1.2-7.	 Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after

coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;6:117–28.

7.1.2 Primary Prevention of SCD in Patients With Ischemic Heart Disease

S7.1.2-1.	 Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. S7.1.2-2.	 Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. S7.1.2-3.	 Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40. S7.1.2-4.	 Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144:440–8. S7.1.2-5.	 Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90. S7.1.2-6.	 Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, et al. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation. Transplant Proc. 2013;45:3659–61. S7.1.2-7.	 Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158–65. S7.1.2-8.	 Gandjbakhch E, Rovani M, Varnous S, et al. Implantable cardioverter-defibrillators in end-stage heart failure patients listed for heart transplantation: results from a large retrospective registry. Arch Cardiovasc Dis. 2016;109:476–85. S7.1.2-9.	 Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation: an UNOS/OPTN analysis. JACC Clin Electrophysiol. 2017;3:33–40. S7.1.2-10.	 Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8. S7.1.2-11.	 Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36. S7.1.2-12.	 Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97:2129–35. S7.1.2-13.	 Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310–8. S7.1.2-14.	 Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi-

brillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT). Circulation. 2006;114:135–42. S7.1.2-15.	 Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco-

nomic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593–600. S7.1.2-16.	 Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards. Circulation. 2006;114:2534–70. S7.1.2-17.	 Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716–26. S7.1.2-18.	 Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80. S7.1.2-19.	 Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34:211–9. S7.1.2-20.	 Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45. S7.1.2-21.	 Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342:1937–45. S7.1.2-22.	 Zaman S, Sivagangabalan G, Narayan A, et al. Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2009;120:194–200. S7.1.2-23.	 Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50. S7.1.2-24.	 Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert

consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014;130:94–125.

7.1.3 Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease

S7.1.3-1.	 Connolly SJ, Dorian P, Roberts RS, et al. Comparison of betablockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–71. S7.1.3-2.	 Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855–62. S7.1.3-3.	 Kettering K, Mewis C, Dornberger V, et al. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2002;25:1571–6. S7.1.3-4.	 Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–21. S7.1.3-5.	 Mallidi J, Nadkarni GN, Berger RD, et al. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease. Heart Rhythm. 2011;8:503–10. S7.1.3-6.	 Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674–83. S7.1.3-7.	 Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–82. S7.1.3-8.	 Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recur-

rent scar-related ventricular tachycardia using electroanatomical

Downloaded from http://ahajournals.org by on October 7, 2026